starpharma | home
home
about starpharma
technology
product pipeline
news room
investor relations
 careers contact us
site search
News Room
 
 
 May 2008
Starpharma reports positive VivaGel clinical study results
12/05/2008
 April 2008
Appendix 4C - Quarterly Cash Flow Report
28/04/2008
Change of Director`s Interest Notice R Dobinson
24/04/2008
Opes Prime overhang cleared
24/04/2008
Dr John Raff Change of Director`s Interest Notice
23/04/2008
First commercial product launch DNT Priostar dendrimers
22/04/2008
Excellence in Biotech Investment CEO Presentation
21/04/2008
SPL7013 Inhibits Clinically Relevant Strains of HPV
21/04/2008
Dendrimer SPL7013 Potential Application for Arthritis
14/04/2008
Presentation Dendrimers New Opportunities to Treat Diseases
10/04/2008
Mr Peter Bartels Change of Director`s Interest Notice
9/04/2008
Shareholding Subject to Security Lending Arrangements
7/04/2008
Starpharma signs agreement with Unilever
7/04/2008
Release of Shares from Escrow
4/04/2008
 March 2008
Change of Director Interest Notice
27/03/2008
Change of Director Interest Notice
26/03/2008
Change of Directors Interest Notice J Fairley and J Raff
17/03/2008
 February 2008
Becoming a Substantial Holder
29/02/2008
CEO Investor Presentation
26/02/2008
2007 Half Yearly Report and Half Year Accounts (0.4MB)
21/02/2008
Final Director's Interest Notice
12/02/2008
Retirement of Director Prof. Peter Colman
12/02/2008
 January 2008
Appendix C - Quarterly Report
31/01/2008
Shareholder Update January 2008
17/01/2008
Expansion of VivaGel US trial and completion of enrollment in herpes trial
8/01/2008
FDA Warning for N-9 - An Opportunity for Vivagel
2/01/2008
 December 2007
CEO to present at Healthcare and Life Sciences Conference
4/12/2007
Signs collaborative research agreement with Stiefel Labs Inc
3/12/2007
 November 2007
VivaGel Awarded International Nanotech Award
19/11/2007
Final Director`s Interest Notice
15/11/2007
Appendix 3B
15/11/2007
Audio stream - AGM CEO’s address
15/11/2007
Results of Meeting
15/11/2007
AGM Chair and CEO presentations
15/11/2007
Resignation of Director
8/11/2007
 October 2007
Appendix 3B
31/10/2007
Appendix C - Quarterly Cashflow Report
31/10/2007
Arterial disease imaging agent funding awarded to Starpharma and Baker Heart Research Institute
31/10/2007
CEO Investor Presentations
23/10/2007
SPL and Durex sign co-development agreement for Vivagel Coated Condoms
16/10/2007
Notice of Annual General Meeting/Proxy Form
12/10/2007
Presents at International Herpes Management Forum Meeting
11/10/2007
Release of Shares from Escrow
9/10/2007
 September 2007
2007 Annual Report (2.1 MB)
27/09/2007
Shareholder Update September 07
4/09/2007
 August 2007
Preliminary Final Report
29/08/2007
Cleansing Statement
24/08/2007
Shareholder Letter - Annual Report default options
23/08/2007
Appendix 3B - Share Placement
23/08/2007
Platinum Partners LLC Invests in Starpharma
21/08/2007
Starpharma`s DNT to Develop Water Purification Technology
8/08/2007
 July 2007
Quarterly Cash Flow Report
31/07/2007
Presents Positive Results of Male Study
24/07/2007
Signs Agreement for Condom Coating Application
18/07/2007
U.S. Trial of VivaGel Commences
10/07/2007
Expiry of Options
3/07/2007
 June 2007
CEO Investor Presentations USA
26/06/2007
Merriman Curhan Ford Initiates Coverage of SPHRY
22/06/2007
Change of Director's Interest Notice
12/06/2007
Change of Director's Interest Notice
8/06/2007
 May 2007
Shareholder Update
28/05/2007
Standard & Poor's Initiates Factual Stock Report Coverage
11/05/2007
CEO presentations USA and Europe
8/05/2007
Priostar Dendrimers Improve Fluorescence Properties
7/05/2007